Lennart Möller

Mr. Lennart Möller

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2025 in International Journal of Cancer
Verified
Journal Article
Open access
LMLennart Möller
Lennart Möller
ASAndras Szentkirályi
Andras Szentkirályi
CEChristine Eisfeld
Christine Eisfeld
IWIna Wellmann
Ina Wellmann
FRFranziska Rees
Franziska Rees
ASAndreas Stang
Andreas Stang
Neuroendocrine neoplasms (NENs) of the colon and rectum are a heterogeneous group of epithelial neoplasms with neuroendocrine differentiation. They include well‐differentiated neuroendocrine tumors (NETs), poorly differentiated neuroendocrine carcinomas (NECs) and mixed neuroendocrine‐non‐neuroendocrine neoplasms (MiNENs). Our aim was to calculate incidence, incidence trends and relative survival for colonic and rectal NETs, NECs, and MiNENs. We analyzed data covering the entire German population recorded between 2009 and 2021, calculating age‐standardized incidence rates, annual percent changes, and the relative 5‐year survival probability for the calendar period 2017–2021. Our comprehensive analyses included 12,602 NEN cases, with 59% located in the rectum. NECs, MiNENs and tumors with colonic location showed higher stages. We observed an increase in the incidence of NETs, particularly in patients aged <55 years, and in the incidence of MiNENs, and a constant incidence of NECs. The relative five‐year survival was high for rectal NETs (95.9%, 95%‐CI 94.6; 97.1) and colonic NETs (81.4%, 95%‐CI 78.3; 84.5) and low for colonic NECs (20.5%, 95%‐CI 17.6; 23.4) and rectal NECs (19.2%, 95%‐CI 15.7; 22.6). The increase in the incidence of NETs might be partly due to colorectal cancer screening, improved diagnostics, and changes in classification of NETs. We attribute the increase in incidence of MiNENs to the recent introduction of this morphological category. Higher stages at diagnosis, a higher proportion of NECs and higher median age at diagnosis may contribute to the less favorable survival probabilities associated with colonic as opposed to rectal location.

6 June 2024 in Cancers
Verified
Journal Article
Open access
PDF file
ASAndreas Stang
Andreas Stang
LMLennart Möller
Lennart Möller
IWIna Wellmann
Ina Wellmann
KCKevin Claassen
Kevin Claassen
HKHiltraud Kajüter
Hiltraud Kajüter
Jürgen C. BeckerJürgen C. Becker
Jürgen C. Becker
Background: To date, only a few population-representative studies have been carried out on the rare Merkel cell carcinoma (MCC). We provide incidence and survival estimates of MCC, including the conditional relative survival. Methods: We analyzed data from the cancer registry of North Rhine-Westphalia, Germany, 2008–2021, covering a population of 18 million. We included all newly diagnosed MCCs and calculated age-standardized (old European Standard population) incidence rates and unconditional and conditional relative survival. Results: Our analysis included 2164 MCC patients. The age-standardized incidence of MCC was 5.2 (men) and 3.8 (women) per million person-years. The 5-year relative survival was 58.8% (men) and 70.7% (women). Survival was lower among men than women in all age–sex groups and was highest for MCC of the upper extremity in both men (68.2%) and women (79.3%). The sex difference in survival is particularly due to the better survival of women with MCC of the head and neck. In terms of survival, the first two years are particularly critical. Conclusions: Our data validate the worse survival among men and highlights a more favorable prognosis for MCCs located on the limbs. The first two years after diagnosis of MCC are the years with the highest excess mortality.

9 December 2024 in Clinical Genitourinary Cancer
Verified
Journal Article
Open access
MKMadeleine J. Karpinski
Madeleine J. Karpinski
KCKevin Claassen
Kevin Claassen
LMLennart Möller
Lennart Möller
JHJohannes Hüsing
Johannes Hüsing
HKHiltraud Kajüter
Hiltraud Kajüter
ASAndreas Stang
Andreas Stang
There is no organized prostate cancer screening in Germany. The aim of this study was to investigate the development of incidence and survival in patients with primary malignant tumors of the prostate in relation to changing recommendations of prostate-specific antigen (PSA) screening in guidelines. Age-standardized incidence rates and 5-year relative survival (RS) (period approach) were calculated using data from the cancer registry North Rhine-Westphalia with the subset of the administrative district Münster respectively for the years 1992-2019. Analyses were stratified according to TNM classification. Until 2008 overall prostate cancer incidence increased, followed by a decrease up to 2017 and another increase thereafter. The same trend was observed in nonmetastatic but not in metastatic prostate cancer. Overall 5-year RS showed an increase of 10 percentage points up to period 2005-2009, followed by a constant RS. 5-year RS of patients with distant metastases remained constant from period 2000-2004 to 2015-2019, while 5-year RS with nonmetastatic prostate cancer and lymph node metastases increased slightly. Overall and nonmetastatic incidence rates reflect changes of recommendation in PSA screening guidelines from the United States. Accordingly, the increase in 5-year RS might be influenced by lead time bias. Incidence and survival of metastatic prostate cancer barely suggest any association with changing PSA screening recommendations. Structured early detection of metastases with additionally applied diagnostic methods might improve 5-year RS rates of metastatic prostate cancer patients.

27 April 2026 in Cancer Epidemiology
Verified
Journal Article
Closed access
FOFlorian Oesterling
Florian Oesterling
LMLennart Möller
Lennart Möller
HKHiltraud Kajüter
Hiltraud Kajüter
ASAndreas Stang
Andreas Stang
MMMarcel Mayer
Marcel Mayer
LNLisa Nachtsheim
Lisa Nachtsheim